CS
ORMP icon

Credit Suisse’s Oramed Pharmaceuticals ORMP Stock Holding History

Credit Suisse’s Portfolio ORMP Stock Details ORMP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-20
Closed – – 4208
2022
Q2 		$0 Sell
20
-20,789
-100% -$111K ﹤0.01% 4197
2022
Q1 		$180K Buy
20,809
+2,686
+15% +$27.5K ﹤0.01% 3398
2021
Q4 		$259K Buy
+18,123
New +$379K ﹤0.01% 4178
2014
Q2 		– Sell
-12,000
Closed -$142K – 4763
2014
Q1 		$142K Buy
+12,000
New +$203K ﹤0.01% 4454
2013
Q3 		– Sell
-15,272
Closed -$125K – 4320
2013
Q2 		$125K Buy
+15,272
New +$126K ﹤0.01% 3973

Other funds holding ORMP

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
JSMC
Jess S. Morgan & Co Los Angeles, California $115M AUM 16.65% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
CSS
Cubist Systematic Strategies Stamford, Connecticut $21B AUM 21.48% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Credit Suisse's ORMP Position: Q3 2022 in Review

Credit Suisse sold out of Oramed Pharmaceuticals (ORMP) in Q3 2022, closing a stake of 20 shares.

Credit Suisse first reported a position in ORMP in Q2 2013 and held it in 5 quarters. The position peaked at $259K in Q4 2021. 71 funds tracked by Wall St. Rank hold ORMP as of Q3 2022.

  • Credit Suisse reported no remaining Oramed Pharmaceuticals position as of Q3 2022 after selling out during the quarter.
  • Credit Suisse sold 20 Oramed Pharmaceuticals shares in Q3 2022.
  • Credit Suisse first reported a position in Oramed Pharmaceuticals in Q2 2013 and held it in 5 quarters.
  • Credit Suisse's Oramed Pharmaceuticals position peaked at $259K in Q4 2021.
  • 71 funds tracked by Wall St. Rank held Oramed Pharmaceuticals as of Q3 2022.

Based on Credit Suisse's 13F filing for Q3 2022, filed 10 Nov 2022.